<code id='D0E08C712C'></code><style id='D0E08C712C'></style>
    • <acronym id='D0E08C712C'></acronym>
      <center id='D0E08C712C'><center id='D0E08C712C'><tfoot id='D0E08C712C'></tfoot></center><abbr id='D0E08C712C'><dir id='D0E08C712C'><tfoot id='D0E08C712C'></tfoot><noframes id='D0E08C712C'>

    • <optgroup id='D0E08C712C'><strike id='D0E08C712C'><sup id='D0E08C712C'></sup></strike><code id='D0E08C712C'></code></optgroup>
        1. <b id='D0E08C712C'><label id='D0E08C712C'><select id='D0E08C712C'><dt id='D0E08C712C'><span id='D0E08C712C'></span></dt></select></label></b><u id='D0E08C712C'></u>
          <i id='D0E08C712C'><strike id='D0E08C712C'><tt id='D0E08C712C'><pre id='D0E08C712C'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:entertainment    Page View:12
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In